Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Astrazeneca looks to power lupus effort over the finish line
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Takeda’s dengue data spell more bad news for Sanofi
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Supernus’s latest failure leaves its future looking dim
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
ASN 2019 preview – fears grow that roxadustat could come up short
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Wright and Stryker embark on a joints venture
Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.